8.21
+0.07(+0.86%)
Currency In USD
| Previous Close | 8.14 |
| Open | 7.57 |
| Day High | 8.45 |
| Day Low | 7.57 |
| 52-Week High | 9.37 |
| 52-Week Low | 1.1 |
| Volume | 915,374 |
| Average Volume | 1.56M |
| Market Cap | 298.04M |
| PE | -4.32 |
| EPS | -1.9 |
| Moving Average 50 Days | 4.43 |
| Moving Average 200 Days | 2.48 |
| Change | 0.07 |
If you invested $1000 in Immuneering Corporation (IMRX) since IPO date, it would be worth $466.74 as of September 12, 2025 at a share price of $8.21. Whereas If you bought $1000 worth of Immuneering Corporation (IMRX) shares 3 years ago, it would be worth $835.2 as of September 12, 2025 at a share price of $8.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25
GlobeNewswire Inc.
Sep 10, 2025 11:00 AM GMT
- Company plans to host an investor call at 8 a.m. ET on September 25 - - Immuneering plans to then share the updated data at the PanCAN Scientific Summit on September 28 - - Additionally, the Company will present a review of preclinical data on Deep
Immuneering Announces Closing of $25 Million Private Placement
GlobeNewswire Inc.
Aug 26, 2025 8:05 PM GMT
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the closing of its previously announced private placement. The p
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clin